[news]

1. Lilly, Novo's bet on heart disease starts to take shape, and 2024 could be a pivotal year for their GLP-1s Endpoints News
2. GLP-1 RAs for CVD: Are Cardiologists Ready? Medscape
3. Semaglutide and Cardiovascular Outcomes in Obesity | NEJM nejm.org
4. Wegovy found to reduce risk of serious heart problems | Health Smart WPMT FOX 43
5. Targeting obesity may be 'highly effective strategy' for treating HFpEF, ASCVD Healio

More...